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Abstract
Background Behavioral and psychological symptoms of
dementia (BPSD) are known predictors of institutional-
ization, lower quality of life, and caregiver distress.
Guidelines recommend initial management with non-
pharmacological means, but antipsychotic drugs are widely
used for the treatment of certain BPSD.
Objectives The objective of the current study is to ana-
lyze the prevalence of BPSD and antipsychotic drug use in
long-term care facilities in Korea.
Methods Retrospective chart review and cross-sectional
analysis was conducted with 529 residents diagnosed with
dementia out of a total 835 residents in 20 long-term care
facilities from October 2011 to April 2012. Basic charac-
teristics of residents such as prevalence of BPSD and
antipsychotic prescriptions were analyzed. BPSD was
determined using the Neuropsychiatric Inventory-Ques-
tionnaire (NPI-Q) assessment tool, and associations with
the use of antipsychotic drugs were investigated.
Results The mean age of the 529 residents was
81.16 ± 8.73 years; 410 (77.5 %) were female. The mean
length of stay in long-term care facilities was
24.19 ± 23.06 months. The primary outcome was a
prescription rate of antipsychotic medications. Of the 529
dementia residents, 143 (27 %) were prescribed antipsy-
chotic medications (quetiapine, risperidone, and olanzap-
ine). Agitation was the most common symptom of BPSD.
Disinhibition and irritability were associated with the use
of antipsychotics in a multiple logistic regression analysis
[respectively P = 0.007 and 0.016 and adjusted odds ratio
(range) = 0.51 (0.31–0.83) and 0.57 (0.36–0.90)].
Conclusion BPSD are common in long-term care facili-
ties in Korea. Twenty-seven percent of dementia residents
in long-term care facilities in Korea were prescribed
antipsychotic medications. Furthermore, antipsychotic drug
use was significantly associated with disinhibition and
irritability in those patients.
1 Introduction
Behavioral and psychological symptoms of dementia
(BPSD) are known predictors of institutionalization [1–3],
lower quality of life [4], and caregiver distress [5, 6].
Guidelines recommend initial management with non-
pharmacological means [7], but antipsychotic drugs are
widely used for the treatment of certain BPSD. One study
showed that 40 % of elderly people with cognitive
impairment in nursing homes took antipsychotic drugs [8].
The widespread use of antipsychotic drugs in nursing
homes has been a concern for many years. Safety data from
randomized clinical trials and observational studies have
led regulatory agencies to issue official warnings on a
possible increased risk of ischemic cerebrovascular events
and all-cause death associated with the use of antipsy-
chotics [9, 10]. Despite US Food and Drug Administration
(FDA) safety warnings, there has been little change in the
rate of antipsychotic prescription in US nursing homes over
K. S. Lee and S.-H. Kim contributed equally as co-first authors.
& Hee-Jin Hwang
ydsfm3624@naver.com
1 Department of Psychiatry, CHA University College of
Medicine, Bundang CHA Hospital, Bundang, Korea
2 Yonsei Woori Getiatric Hospital, Goyang, Korea
3 Department of Family Medicine, International St. Mary’s
Hospital, Catholic Kwandong University College of
Medicine, 25, Simgok-ro 100beon-gil, Seo-gu,
Incheon 404-834, Korea
Drugs - Real World Outcomes (2015) 2:363–368
DOI 10.1007/s40801-015-0047-0
the past decade [11–15]. On the other hand, there have
been updates regarding the off-label use of atypical
antipsychotics for BPSD [16], such as the comparative
effectiveness reviews issued by the Agency for Healthcare
Research and Quality in the USA [17]. There were small
but statistically significant benefits from using aripiprazole,
olanzapine, and risperidone compared with placebo in the
treatment of BPSD [17]. Although the use of antipsychotics
in BPSD is off-label, antipsychotics are still the best
pharmacological short-term treatment option for BPSD-
related aggression/agitation [16].
There is wide variation across Organization for Eco-
nomic Co-operation and Development (OECD) countries
in the provision of formal long-term care (LTC) services
for the elderly. A common concern has been the quality of
formal LTC services, particularly in nursing homes [18,
19]. Nursing homes, themselves, involve a heterogeneous
range of resident cases and services rendered, often based
on country and setting [20]. The use of antipsychotics is
considered an indicator of quality of care in nursing
homes. Though nursing homes play an important role in
providing care for the elderly, no data are currently
available on the use of psychoactive medications in Korea
nursing homes.
The aim of this study was to describe the pattern of use
of antipsychotic drugs in Korean nursing home residents
with dementia and to identify individual sociodemographic
and clinical characteristics and facility-related factors that
are associated with their use.
2 Methods
The sample data for this retrospective, cross-sectional
analysis was derived from the Long-term care of Old
people Via KorEan nursing home network (LOVE) study,
conducted in 20 Korean LTC facilities from October 2011
to April 2012. A total of 835 residents were recruited from
20 nursing homes. Of these, 41 patients were excluded due
to incomplete data and 265 patients due to no diagnosis of
dementia. The study was approved by the Ethics Review
Board at Myoung-Ji Hospital.
Comprehensive assessment, including medical, psy-
chosocial, and functional evaluation, was performed by a
geriatrics team [21]. The following variables were included
in the analysis: gender, age (years), grade of long-term care
(Grade 1 = greater dependency and the requirement for
high-level care), and history of co-morbidities such as
hypertension, stroke, diabetes mellitus, osteoporosis,
Parkinson’s disease, and congestive heart failure. All
medical diagnoses, including dementia, were made by the
physicians in charge of the resident, following the usual
International Classification of Diseases diagnostic criteria.
BPSD was determined using the Neuropsychiatric Inven-
tory-Questionnaire (NPI-Q) assessment tool, and associa-
tions with the use of antipsychotic drugs were investigated.
The NPI Questionnaire is a validated caregiver-completed
questionnaire derived from the original NPI. The NPI-Q is
used to measure 12 categories of behavioral disturbance:
delusions, hallucinations, anxiety, depression/dysphoria,
agitation/aggression, elation/euphoria, disinhibition, irri-
tability/lability, apathy/Indifference, motor disturbance,
night-time behavior problems, and problems with appetite/

















Diabetes mellitus 134 (25.3)
Osteoarthritis 84 (15.9)
Osteoporosis 66 (12.5)
Parkinson’s disease 34 (6.4)
Heart failure 12 (2.3)
Medications
Antipsychotics (N05A) 143 (27.0)
Quetiapine (N05AH04) 120 (22.7)
Risperidone (N05AX08) 25 (4.7)
Olanzapine (N05AH03) 21 (4.0)
More than two drugs 23 (4.3)
Anti-dementia drugs (N06D)
Donepezil (N06DA02) 97 (18.3)
Memantine (N06DX01) 30 (5.7)
Other 10 (1.9)
Antidepressants (N06A)
Selective serotonin reuptake inhibitor (N06AB) 14 (2.6)
Trazodone (N06AX05) 27 (5.1)
Tricyclic antidepressant (N06AA) 10 (1.9)
Other 10 (1.9)
Anticonvulsants (N03A) 24 (4.5)
Anxiolytics (N05BA) 22 (4.2)
Grade 1 greater dependency and the requirement for high-level care
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eating. The questionnaire is completed by a caregiver and
determines whether the patient exhibits each of the
behaviors [22]. Drugs were classified according to the
Anatomical Therapeutic Chemical (ATC) classification
system [23]. Psychotropic drugs were categorized as fol-
lows: any psychotropic (ATC-codes N05 and N06),
antipsychotics (N05A), anxiolytics (N05B), hypnotics
(N05C), and antidepressants (N06A).
Resident baseline characteristics were described using
t tests for continuous variables and Chi-square tests for
categorical variables. NPI-Q characteristics were described
according to the use of antipsychotic drugs, and differences
in these characteristics were identified by Chi-square tests.
To examine factors associated with antipsychotic drug use,
multiple logistic regression analysis was performed. The
dependent variable was the antipsychotic drug use, and the
Table 2 Prevalence of behavioral and psychological symptoms of dementia (BPSD) stratified by antipsychotic drug use
BPSD No antipsychotic medication, n = 386 (%)a Antipsychotic medication,(b) n = 143 (%)(a) P valuec
Delusions 142 (36.8) 45 (31.5) 0.256
Severity 2.11 ± 0.76 2.13 ± 0.84 0.836
Distress 2.8 ± 1.36 2.73 ± 1.44 0.790
Hallucinations 104 (26.9) 44 (30.8) 0.384
Severity 2.25 ± 0.79 2.27 ± 0.76 0.859
Distress 2.81 ± 1.47 3.11 ± 1.47 0.250
Agitation 205 (53.1) 66 (46.2) 0.155
Severity 2.27 ± 0.79 2.30 ± 0.84 0.788
Distress 2.98 ± 1.40 3.04 ± 1.57 0.749
Depression 199 (51.6) 75 (52.4) 0.855
Severity 2.06 ± 0.75 1.93 ± 0.83 0.226
Distress 2.41 ± 1.32 2.21 ± 1.34 0.281
Anxiety 107 (27.7) 40 (28.0) 0.954
Severity 1.99 ± 0.81 1.95 ± 0.75 0.782
Distress 2.36 ± 1.45 2.45 ± 1.40 0.720
Euphoria 99 (25.6) 36 (25.2) 0.912
Severity 1.87 ± 0.65 1.97 ± 0.77 0.438
Distress 1.99 ± 1.27 1.83 ± 1.48 0.545
Apathy 137 (35.5) 46 (32.2) 0.475
Severity 2.66 ± 0.73 2.00 ± 0.82 0.047
Distress 2.64 ± 1.38 2.07 ± 1.22 0.012
Disinhibition 155 (40.2) 36 (25.2) 0.001
Severity 2.23 ± 0.75 2.39 ± 0.65 0.246
Distress 2.93 ± 1.46 3.06 ± 1.41 0.637
Irritability 178 (46.1) 48 (33.6) 0.010
Severity 2.18 ± 0.80 2.38 ± 0.76 0.130
Distress 2.79 ± 1.43 2.90 ± 1.42 0.656
Aberrant motor behavior 123 (31.9) 43 (30.1) 0.693
Severity 2.30 ± 0.75 2.42 ± 0.63 0.355
Distress 3.11 ± 1.39 2.72 ± 1.32 0.115
Night-time behavior 155 (40.2) 52 (36.4) 0.427
Severity 2.25 ± 0.74 2.35 ± 0.62 0.406
Distress 3.05 ± 1.39 2.75 ± 1.33 0.182
Appetite/eating behavior 73 (18.9) 18 (12.6) 0.087
Severity 2.01 ± 0.74 1.94 ± 0.80 0.726
Distress 2.21 ± 1.35 1.89 ± 1.57 0.391
a Values are presented as n (%) for prevalence of BPSD, mean ± SD for severity and distress
b Prescribed antipsychotic medications were quetapine, risperidone, and olanzapine
c P value from Chi-square test for prevalence of BPSD, t test for severity and distress
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independent predictors were age, sex, the grade of long-
term care, the length of stay, and other drugs. All analyses
were conducted using SPSS 18.0 software for Windows.
3 Results
Table 1 shows the baseline characteristics of residents with
dementia. The mean age of the total 529 dementia residents
was 81.16 ± 8.73 years (mean ± SD), and 410 (77.5 %)
of the residents were female. The average length of stay in
long-term care facilities was 24.19 ± 23.06 months. In the
143 (27 %) residents currently using antipsychotics [que-
tiapine (N05AH04), risperidone (N05AX08), and olanza-
pine (N05AH03)], the most commonly prescribed
medication in these residents; 25.9 % were taking an anti-
dementia drug [donepezil (N06DA02), memantine
(N06DX01), and other].
Tricyclic antidepressants, which are inappropriate in
dementia because of anticholinergic vulnerability, were
prescribed in 10 (1.9 %) residents. Agitation (51.2%) was
one of the most common of the behavioural and psycho-
logical symptoms of dementia (see Table 2). Of the resi-
dents taking an anti-dementia drug, 69.7 % were taking
quetiapine, 14.5 % risperidone, and 15.8 % olanzapine
(Table 3). Disinhibition and irritability were associated
with the use of antipsychotics in a multiple logistic
regression analysis. Indeed, the multiple logistic regression
analysis showed that those who exhibited disinhibition and
irritability were at increased risk of being prescribed an
antipsychotic drug (Table 4).
4 Discussion
A diagnosis of dementia was present in 63.3 % of 835
residents in 20 long-term care facilities in Korea, and
27.0 % of these residents had been prescribed an antipsy-
chotic drug. A previous study showed that of 1334 non-
agenarian residents in long-term care, 30 % has been pre-
scribed an antipsychotic medication [24]. In 2005, Hosia-
Randell and Pitka¨la¨ [25] stated that 31.3 % of non-age-
narian residents in nursing homes in Helsinki were taking
antipsychotics. The present results are also in agreement
with the earlier findings of studies by Oborne (24.5 %) [26]
and Briesacher (27.6 %) [12].
A number of limitations must be mentioned with regard
to the present study. First, the study was cross-sectional,
Table 3 Prevalence of antipsychotic use in dementia patients stratified by anti-dementia drug use
Donepezil (N06DA02) Memantine (N06DX01) Other drugs No antidementia drug use
Quetiapine (N05AH04) 31 (25.8) 16 (13.3) 6 (5.0) 67 (55.8)
Risperidone (N05AX08) 6 (24.0) 3 (12.0) 2 (8.0) 14 (56.0)
Olanzapine (N05AH03) 7 (33.3) 5 (23.8) 0 9 (42.9)
Values are presented as n (%)
Table 4 Logistic regression
analysis for antipsychotic use in
long-term care facility residents
with dementia
BPSDa b Standard error P value Adjusted ORb (95 % CIc)
Delusions -0.254 0.238 0.286 0.78 (0.48–1.24)
Hallucinations 0.287 0.244 0.239 1.33 (0.83–2.15)
Agitation -0.106 0.225 0.637 0.90 (0.58–1.40)
Depression 0.167 0.225 0.457 1.18 (0.76–1.83)
Anxiety -0.760 0.252 0.763 0.93 (0.57–1.52)
Euphoria 0.229 0.253 0.364 1.26 (0.77–2.07)
Apathy 0.044 0.235 0.850 1.05 (0.66–1.66)
Disinhibition -0.673 0.247 0.007 0.51 (0.31–0.83)
Irritability -0.563 0.233 0.016 0.57 (0.36–0.90)
Aberrant motor behavior -0.045 0.242 0.854 0.96 (0.60–1.54)
Night-time behavior -0.152 0.230 0.508 0.86 (0.55–1.35)
Appetite/eating behavior -0.572 0.328 0.081 0.56 (0.30–1.07)
Adjusted for age, sex, grade of long term care, and length of stay
a Behavioral and psychological symptoms of dementia
b Odds ratio
c Confidence interval
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thus providing a comprehensive snapshot at one point in
time but without the ability to establish causal relation-
ships. Second, the facilities included in the study were not
randomly selected. As such, they may not be nationally
representative or generalizable to all long-term care resi-
dents in Korea. There is also a possibility of selection bias
as geriatricians may have a tendency to prescribe antipsy-
chotic drugs or that patients with more severe BSPD are
primarily admitted to facilities in which such a geriatrician
was known to be available. Nevertheless, the strengths of
this work should not be overlooked. The study included a
relatively large sample to illustrate current antipsychotic
use in Korean nursing homes.
Behavioral symptoms and dementia have previously been
shown to be the main predictors of antipsychotic prescrip-
tions in nursing home residents [27, 28] and the results of our
study support this finding. Continuous prescription of
antipsychotics here and in another study [29] is not concor-
dant with current treatment recommendations, and the need
for continued treatment should be reviewed regularly every
6 months [30–32]. On the other hand, antipsychotics showed
small but statistically significant benefits in the treatment of
BPSD and are still the short-term pharmacological treatment
option for BPSD associated with disinhibition and irritability
in long-term care facilities in Korea.
5 Conclusion
BPSD are common in long-term care facilities in Korea.
Twenty-seven percent of dementia residents in long-term
care facilities in Korea were prescribed antipsychotic
medications. Furthermore, antipsychotic drug use was
significantly associated with disinhibition and irritability in
those patients.
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